Detalhe da pesquisa
1.
Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial.
Oncologist
; 25(8): e1233-e1241, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32476162
2.
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Cancer Cell
; 36(4): 444-457.e7, 2019 10 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31588020
3.
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Cancer Cell
; 37(3): 420, 2020 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-32183953